Onesource Specialty Pharma Limited (NSE: ONESOURCE) and Sai Life Sciences Limited (NSE: SAILIFE) are both listed in the Pharmaceutical CDMO and CRO Services industry. Onesource Specialty Pharma has a market capitalisation of ₹17,868 Cr and Sai Life Sciences ₹32,761 Cr, as of 9 Nov 2026. Return on equity is -1.26% for Onesource Specialty Pharma and 15.13% for Sai Life Sciences. Over one year, Onesource Specialty Pharma's share price is down 14.1% and Sai Life Sciences's is up 99.0%.
| Metric | Onesource Specialty Pharma | Sai Life Sciences |
|---|---|---|
| NSE Symbol | ONESOURCE | SAILIFE |
| BSE Code | 544292 | 544306 |
| Share Price | ₹1,613.50 | ₹1,836.00 |
| Market Cap | ₹17,868 Cr | ₹32,761 Cr |
| P/E Ratio | Not meaningful (loss) | 93.9 |
| Return on Equity | -1.26% | 15.13% |
| Return on Assets | -0.03% | 8.57% |
| Beta (1Y) | 0.25 | 0.4 |
| 1-Year Price Change | -14.1% | +99.0% |
| 3-Month Price Change | +2.4% | +28.7% |
| 52-Week Range | ₹1,057.00 – ₹1,917.80 | ₹783.85 – ₹1,897.30 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹516 Cr | ₹659 Cr |
| Quarterly Net Profit | ₹57 Cr | ₹98 Cr |
| Net Margin | 11.1% | 14.9% |
| EPS (Basic, Quarter) | — | ₹4.63 |
| Results Basis | consolidated | consolidated |
| Headquarters | Bengaluru, Karnataka | Hyderabad, Telangana |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoin…
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.
Sai Life Sciences has a market capitalisation of ₹32,761 Cr, against ₹17,868 Cr for Onesource Specialty Pharma as of 9 Nov 2026, about 1.8 times the size by market cap.
Onesource Specialty Pharma has a return on equity of -1.26% and Sai Life Sciences 15.13%.
Onesource Specialty Pharma's share price is down 14.1% over one year and Sai Life Sciences's is up 99.0%.
Onesource Specialty Pharma reported revenue of ₹516 Cr and net profit of ₹57 Cr for Q2 FY27. Sai Life Sciences reported revenue of ₹659 Cr and net profit of ₹98 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.